Secretagogue-specific effects of interleukin-1 on gastric acid secretion

Am J Physiol. 1991 Oct;261(4 Pt 1):G559-64. doi: 10.1152/ajpgi.1991.261.4.G559.


Interleukin-1 beta (IL-1 beta) has recently been shown to reduce the severity of experimental gastroduodenal damage and to inhibit acid secretion in the pylorus-ligated rat. In the present study, the effects of IL-1 beta on pentagastrin-stimulated acid secretion were compared with those of two other cytokines, namely IL-1 alpha and tumor necrosis factor (TNF) alpha. Also, the effects of IL-1 beta on gastric acid secretion stimulated by bethanechol or histamine were assessed. Anesthetized rats were pretreated intravenously with one of the cytokines, at doses in the 0.1-5 micrograms/kg range, 30 min before starting an intravenous infusion of pentagastrin. TNF alpha failed to significantly affect acid secretion, whereas IL-1 alpha and IL-1 beta exhibited significant inhibitory effects. For example, at a dose of 5 micrograms/kg, IL-1 alpha and IL-1 beta reduced acid secretion by 33 and 80%, respectively. The inhibitory effects of IL-1 beta on acid secretion could be completely inhibited by preincubation with an antibody directed against IL-1 beta but not by pretreatment with indomethacin (5 mg/kg sc) or by bilateral vagotomy. If acid secretion was stimulated by intravenous infusions of histamine or bethanechol, neither IL-1 beta nor TNF alpha produced significant inhibitory effects. Inhibition of acid secretion by IL-1 was also observed when the IL-1 was administered subsequent to stimulation by pentagastrin administration. These results demonstrate that IL-1 beta is an extremely potent inhibitor of acid secretion stimulated by pentagastrin but not that stimulated by histamine or bethanechol, through a mechanism that is at least in part independent of the vagus nerve and of prostaglandin synthesis. IL-1 alpha is less potent as an inhibitor of gastric acid secretion, whereas TNF appears to be inactive. Because pentagastrin-stimulated acid secretion could be completely inhibited by a histamine H2-receptor antagonist (cimetidine) and because IL-1 had no effect on histamine-stimulated acid secretion, it is possible that IL-1 exerts its antisecretory actions by inhibiting pentagastrin-stimulated histamine release.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies / immunology
  • Bethanechol
  • Bethanechol Compounds / pharmacology*
  • Cimetidine / pharmacology
  • Gastric Acid / metabolism*
  • Histamine / pharmacology*
  • Indomethacin / pharmacology
  • Injections, Intravenous
  • Interleukin-1 / immunology
  • Interleukin-1 / pharmacology*
  • Male
  • Pentagastrin / pharmacology*
  • Rats
  • Rats, Inbred Strains
  • Tumor Necrosis Factor-alpha / pharmacology
  • Vagotomy


  • Antibodies
  • Bethanechol Compounds
  • Interleukin-1
  • Tumor Necrosis Factor-alpha
  • Bethanechol
  • Cimetidine
  • Histamine
  • Pentagastrin
  • Indomethacin